What is the best way to evaluate the toxicity of biomaterials for drug delivery?

Biomaterials are substances that can interact with biological systems for medical purposes, such as drug delivery, tissue engineering, or diagnostics. However, not all biomaterials are safe and biocompatible, meaning they do not cause adverse reactions or toxicity in the body. Therefore, it is essential to evaluate the toxicity of biomaterials before using them for drug delivery applications. In this article, you will learn about the best methods and criteria to assess the toxicity of biomaterials for drug delivery.

1 Types of toxicity

Toxicity is the degree to which a substance can harm living organisms, such as cells, tissues, organs, or whole organisms. There are different types of toxicity that can affect the safety and efficacy of biomaterials for drug delivery, such as cytotoxicity which is the ability of a substance to damage or kill cells in vitro, usually measured by cell viability, proliferation, morphology or function assays; genotoxicity which is the ability of a substance to cause mutations or DNA damage in cells, usually measured by comet, micronucleus or mutation assays; immunotoxicity which is the ability of a substance to trigger unwanted immune responses such as inflammation, allergy or autoimmunity, usually measured by cytokine, antibody or hypersensitivity assays; and biodegradation which is the ability of a substance to degrade or dissolve in the body, usually measured by mass loss, molecular weight or degradation products assays.

Add your perspective

Vivek Dadhania, PhD, DABT, ERT

Founder SciQra I Board-Certified Toxicologist I Product Safety l Drug Discovery Scientist l NIPER
Report contribution
Toxicity is a paramount concern when evaluating the safety and effectiveness of biomaterials used in drug delivery. Understanding diverse types of toxicity is pivotal for i) conducting a comprehensive assessment, and ii) ensuring patient safety and the effectiveness of medical treatments. The type of required toxicological study mainly depends on the type and duration of exposure. Types of Toxicity: Mainly two types: Systemic Toxicity: How biomaterials affect the entire organism, including vital organs and physiological functions. Local Toxicity: Impact of biomaterials at the site of administration/contact. It focuses on issues such as irritation, inflammation, or other localized adverse reactions.

Like

Unhelpful

2 Factors influencing toxicity

The toxicity of biomaterials for drug delivery is determined by a variety of factors, such as the material properties, drug properties, delivery route, and exposure time. The chemical composition, structure, size, shape, surface charge, and functionalization of the biomaterials can all influence their interaction with biological molecules, cells, and tissues. Additionally, the type, dose, release rate, and pharmacokinetics of the drug loaded in the biomaterials can affect their toxicity. The mode of administration of the biomaterials is also important; for example oral, intravenous, subcutaneous or intramuscular delivery routes can determine their distribution and elimination in the body. Finally, the duration and frequency of contact between the biomaterials and the biological system can influence their toxicity.

Add your perspective

Vivek Dadhania, PhD, DABT, ERT

Founder SciQra I Board-Certified Toxicologist I Product Safety l Drug Discovery Scientist l NIPER
Report contribution
Ensuring the safety of biomaterials in drug delivery is a complex task, influenced by properties like chemical composition, structure, and shape. Metals provide strength but may lack responsiveness, ceramics are strong and less conductive, and polymers offer versatility and responsiveness. Drug characteristics, including pharmacokinetics and pharmacodynamics, matter greatly. Delivery routes significantly impact safety. Understanding biodegradation is vital. Finally, Patients' genetic variations and health must be factored in for comprehensive safety evaluations.

Like

Unhelpful

3 Methods to evaluate toxicity

Evaluating the toxicity of biomaterials for drug delivery can be done through a variety of methods, from in vitro to in vivo to in silico approaches. In vitro methods use cultured cells or tissues to test the toxicity of biomaterials in a controlled environment, such as a petri dish or a bioreactor. These are fast, cheap, and reproducible, but they may not reflect the complexity and variability of the biological system in vivo. In vivo methods use animals or humans to test the toxicity of biomaterials in a realistic setting, but these are more expensive, time-consuming, and ethically challenging. Lastly, in silico methods use computational models or simulations to predict the toxicity of biomaterials based on their properties, interactions, and mechanisms. While these are useful for screening and optimization, they may not capture all the factors and uncertainties involved in the toxicity of biomaterials.

Add your perspective

William W.

MD/PhD Candidate | Harrington Scholar
Report contribution
Here are several methods that can be used to evaluate toxicity in vitro: MTT Assay: Measures cell viability by converting a yellow tetrazolium salt to purple formazan crystals in live cells. Lactate Dehydrogenase (LDH) Release: Assesses membrane integrity by measuring LDH enzyme leakage from damaged cells. Caspase Activation Assays: Detect apoptosis by identifying activated caspases, which are enzymes involved in programmed cell death. Comet Assay: Visualizes DNA damage in individual cells using gel electrophoresis, where damaged DNA appears as a "comet tail". High-Content Screening (HCS): Uses automated microscopy to quantify cellular changes like morphology, protein expression, and localization in response to drug exposure.

Like

Unhelpful
Vivek Dadhania, PhD, DABT, ERT

Founder SciQra I Board-Certified Toxicologist I Product Safety l Drug Discovery Scientist l NIPER
Report contribution
Methods for assessing the toxicity of biomaterials in drug delivery encompass a wide array of approaches. These include computational tools for predictive toxicology (in silico), in vitro studies using cell cultures, in vivo studies using animal models, and finally clinical trials for assessing toxicity in human subjects. Beginning with the physicochemical characterization of the materials is a key consideration. These methods assess the hazardous properties of the materials, biomaterial compatibility, inflammatory responses, immunotoxicity, target organ toxicity, genotoxicity, and more, providing a comprehensive picture of potential risks associated with their use. These techniques help identify potential areas of concern.

Like

Unhelpful

4 Criteria to evaluate toxicity

When evaluating the toxicity of biomaterials for drug delivery, different criteria may be applicable depending on the specific application, goal, and regulatory framework. Generally speaking, safety is a key factor - the biomaterials should not cause any significant harm or damage to the biological system. Additionally, biocompatibility must be taken into consideration, as the biomaterials should not induce any unwanted immune responses. Furthermore, efficacy is essential for achieving the desired therapeutic effect. The biomaterials must also remain stable during storage, transport, and delivery. Lastly, clearance is also important; the biomaterials should be eliminated or metabolized by the body without causing long-term toxicity.

Add your perspective

Vivek Dadhania, PhD, DABT, ERT

Founder SciQra I Board-Certified Toxicologist I Product Safety l Drug Discovery Scientist l NIPER
Report contribution
Criteria for evaluating the toxicity of biomaterials in drug delivery can vary based on multiple factors. These criteria encompass the identification of adverse effects, establishing dose-response relationships, and ensuring relevance to the intended clinical use. Furthermore, other criteria, such as considering the patient population and potential long-term effects, may be employed to provide a comprehensive assessment of biomaterial toxicity, contributing to safer and more effective drug delivery systems. Finally, taking the regulatory framework into consideration is crucial.

Like

Unhelpful

5 Challenges and opportunities

The evaluation of the toxicity of biomaterials for drug delivery is a complex task, as it involves various factors, methods, and criteria which can differ depending on the context and application. To improve the evaluation of toxicity, there is a need for more standardized and harmonized protocols, guidelines, and criteria for consistency, comparability, and validity of results. Additionally, there should be more innovative and advanced methods and tools such as microfluidic devices or artificial intelligence to increase the efficiency, accuracy, and relevance of the toxicity assessment. Lastly, there is a need to translate and integrate the toxicity data from different sources and levels to provide a comprehensive view of the toxicity of biomaterials for drug delivery to enable their clinical development and approval.

Add your perspective

Vivek Dadhania, PhD, DABT, ERT

Founder SciQra I Board-Certified Toxicologist I Product Safety l Drug Discovery Scientist l NIPER
Report contribution
Evaluating biomaterial toxicity is complex, given the body's diverse environmental conditions and patient variability. Designing adaptable biomaterials that cater to individual needs while minimizing harm is crucial. It's an interdisciplinary endeavor, involving biology, chemistry, and medicine. Ethical considerations focus on humane treatment in toxicity studies, while regulatory compliance ensures safety assessments meet standards. Further advancements in biomaterial design and testing methods can offer opportunities for safer drug delivery systems. Responsive materials, designed to react to physiological cues, can reduce toxicity and enhance therapeutic efficacy.

Like

Unhelpful

6 Here’s what else to consider

This is a space to share examples, stories, or insights that don’t fit into any of the previous sections. What else would you like to add?

Add your perspective

Vivek Dadhania, PhD, DABT, ERT

Founder SciQra I Board-Certified Toxicologist I Product Safety l Drug Discovery Scientist l NIPER
Report contribution
In the field of drug delivery, researchers are advancing, creating responsive biomaterials. Biocompatibility remains a central challenge for various medical applications. This endeavor involves uncovering physiological intricacies to develop adaptable biomaterials. Breakthroughs in molecular immunology hold promise for enhancing biocompatibility. Future prospects include designing versatile polymer libraries to customize drug delivery. Amidst challenges and opportunities, the pursuit of safer and more effective drug delivery materials drives medical science forward.

Like

Unhelpful

What is the best way to evaluate the toxicity of biomaterials for drug delivery?

1

2

3

4

5

6

1 Types of toxicity

2 Factors influencing toxicity

3 Methods to evaluate toxicity

4 Criteria to evaluate toxicity

5 Challenges and opportunities

6 Here’s what else to consider

Bioengineering

Rate this article

Thanks for your feedback

More articles on Bioengineering

More relevant reading